Oncolytic viruses have been combined with standard cancer therapies to increase therapeutic efficacy. Given the sequential activation of herpes viral genes (herpes simplex virus-1, HSV-1) and the temporal cellular changes induced by ionizing radiation, we hypothesized an optimal temporal sequence existed in combining oncolytic HSV-1 with ionizing radiation. Murine U-87 glioma xenografts were injected with luciferase encoding HSV-1, and ionizing radiation (IR) was given at times before or after viral injection. HSV-1 replication and tumor-volume response were followed. Radiation given 6-9 h after HSV-1 injection resulted in maximal viral luciferase expression and infectious viral production in tumor xenografts. The greatest xenograft regression was also seen with radiation given 6 h after viral injection. We then tested if HSV-1 replication had a dose response to ionizing radiation. HSV-1 luciferase expression exhibited a dose response as xenografts were irradiated from 0 to 5 Gy. There was no difference in viral luciferase expression as IR dose increased from 5 Gy up to 20 Gy. These results suggest that the interaction of IR with the HSV-1 lytic cycle can be manipulated for therapeutic gain by delivering IR at a specific time within viral replicative cycle.
INTRODUCTION
High-grade gliomas remain one of the most therapy-resistant tumors. Current therapy consists of maximal surgical resection followed by radiotherapy and chemotherapy. 1 However, median survival for the most aggressive tumors, glioblastoma multiforme, is 12-14 months. The predominant site of tumor recurrence following both surgery and radiation is local. 2 As most tumor recurrences are within the initial tumor bed, direct injection of attenuated oncolytic viruses such as herpes simplex virus-1 (HSV-1) has been proposed as an adjuvant treatment and utilized in Phase I clinical trials for high-grade gliomas. [3] [4] [5] [6] [7] HSV-1 is a double-stranded DNA virus expressing its genes in a sequential cascade of immediate-early (a), early (b), and late (g) genes. 8 Immediate-early genes encode for viral transcriptional regulators. Early viral genes predominantly encode for proteins involved in viral DNA synthesis. Late genes largely encode structural proteins used in progeny virions. Oncolytic viruses have been genetically engineered by deleting specific viral genes in order to restrict viral replication to cancer cells and also attenuate virulence to increase patient safety. 7, 9 A major strategy has focused on deleting the g 1 34.5 late gene of HSV-1, which in part mediates neurovirulence. 10 Phase I clinical trials in patients with glioma have been completed with neuro-attenuated HSV-1 deleted of g 1 34.5 that have demonstrated the safety and feasibility of this approach. [4] [5] [6] However in creating clinically safe, replication-competent viruses, the therapeutic trade-off is decreased viral replication to maintain safety that hampers anti-tumor efficacy.
We and others have shown that mutant HSV-1 and other classes of oncolytic viruses (adenovirus, measles virus, reovirus, VSV) can be combined with ionizing radiation (IR) to improve tumor xenograft control in experimental animal tumor model systems. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Specifically, g 1 34.5 deleted HSV-1 combined with IR resulted in increased viral replication and glioma-xenograft regression in hindlimb and orthotopic preclinical murine glioma models. 11, 17 Mechanistic studies have elucidated multiple pathways through which IR enhances viral replication. The HSV-1 immediate-early gene product ICP0 has been reported to interfere with DNA repair following irradiation of glioma cells resulting in increased tumor cell death. 18 IR also increases transcription of cellular genes that trans-complement the functions of deleted viral genes. IR-enhanced expression of cellular ribonucleotide reductase assists the replication of viruses deleted of viral ribonucleotide reductase. 19 Another example of trans-complementation involves HSV-1 viruses deleted of g 1 34.5. Growth arrest and DNA damage 34 is a cellular homologue to the HSV-1 gene g 1 34. 5 (ref. 24) . Growth arrest and DNA damage 34 is upregulated following IR and has been shown to increase the replication of HSV-1 viruses deleted in g 1 34. 5 (refs 20, 21, 25) . A third mechanism by which IR can enhance viral replication is by increased expression of viral proteins through upregulation of viral promoters. It has been shown that IR can enhance transcription of late HSV-1 viral promoters by activating the p38 mitogen-activated protein kinase pathway. 22 The elucidation of mechanisms through which IR enhances viral replication predicts that sequencing of IR and oncolytic viruses may be clinically relevant.
The current series of studies aimed to define optimal parameters for combining oncolytic HSV-1 and IR for high-grade glioma therapy. Our previous studies have shown that flank and orthotopic glioma models for studying the combination of IR and oncolytic HSV-1 produce similar results. 11, 17 We therefore utilized the flank glioma model to gain understanding in how to best combine oncolytic HSV with IR. Given that the effects of radiation are specific to different phases of the cell cycle and viral replication proceeds in a sequential cascade, we hypothesized an optimal time to deliver IR during the replicative cycle of oncolytic HSV-1 may exist to maximize oncolytic HSV-1 replication. Such a strategy could provide a rational basis for sequencing radiotherapy and oncolytic viral therapy that will facilitate developing future clinical trials.
RESULTS

Delivering radiation during onset of late viral gene expression results in increased oncolytic viral gene expression
The cellular effects of radiation are specific to different phases of the cell cycle. Viral replication requires a temporal expression of viral genes, and IR has been previously demonstrated to enhance late viral promoter genes. We hypothesized an optimal time to deliver IR during the replicative cycle of oncolytic HSV-1 to maximize HSV-1 replication existed. R2636 is a neuro-attenuated HSV-1 deleted in both copies of g 1 34.5 and encodes the luciferase gene. 22 R2636 was injected into glioma xenografts in the hindlimb of athymic nude mice on day 0 at time 0 h. In irradiated glioma xenografts, 20 Gy was given either before (6 h) or after (0.5, 6, 12, or 24 h) viral injection. Glioma xenografts were serially imaged on days 1, 2, 3, 4, 5 and 7 days post infection to detect viral luciferase expression ( Figure 1a) . The photon flux from non-irradiated R2636 injected glioma xenografts on day 1 was arbitrarily set to 1, and photon flux for all other measurements were expressed relative to this value. In nonirradiated R2636 injected glioma xenografts, luciferase expression increased up to day 4 (2.7-fold) post injection after which it declined. In general, all irradiated glioma xenografts expressed higher levels of viral luciferase compared with non-irradiated glioma xenografts. Notably when IR was given at 6 h following R2636 injection, a 3.5-fold increase in luciferase expression was observed compared with non-irradiated R2636 luciferase expression at day 4 post injection (P¼0.047; Figure 1a ).
Enhanced oncolytic viral gene expression following IR results in increased infectious viral particle production We next determined if IR-enhanced viral gene expression resulted in increased infectious viral particle formation within glioma xenografts. R3616, the prototypical neuro-attenuated HSV-1 deleted for both copies of g 1 34.5, was injected into glioma xenografts and 20 Gy was given either before or after viral injection. 13 Glioma xenografts were harvested 3 days post viral injection and infectious viral particles were quantified ( Figure 2 ). Infectious viral particles were normalized to non-irradiated R3616 injected glioma xenografts at day 3. Similar to the in-situ imaging results, IR delivered 6-9 h post viral injection resulted in the highest recovery of infectious viral particles, 2.3-2.9-fold (P¼0.056). Interestingly, IR delivered 12 h post infection did not result in as much infectious viral particle production, but IR given Influence of timing sequence of oncolytic HSV-1 and radiation on HSV-1 progeny production. Infectious viral particles were quantified from xenografts harvested 3 days after injection with R3616 and irradiated with 20 Gy before or after viral injection. Viral particle production was normalized to non-irradiated R3616 infected glioma xenografts.
24 h post infection resulted in levels of infectious particles similar to when IR was delivered 6-9 h post infection. These results may be explained by the fact that it takes approximately 16-18 h for HSV-1 to replicate, therefore, IR giving 24 h after infection may represent 6-8 h into the course of the replicative cycle of progeny virus from the initial viral injection.
Optimal timing of oncolytic HSV-1 and IR results in increased tumor-xenograft regression As oncolytic HSV-1 and IR sequencing resulted in differential levels of viral gene expression and infectious viral particle production, we next determined whether IR and viral sequencing translated to increased glioma-xenograft regression. Glioma xenografts treated as described in Figure 1a were serially imaged to assess tumor cell destruction. The greatest glioma-xenograft regression was observed with IR delivered 6 h after R2636 injection, correlating directly with maximal luciferase expression (Figures 1a and b) . Glioma-xenograft regression for this treatment schedule was significantly increased by day 8 compared with non-irradiated glioma xenografts (P¼0.00018), and importantly also increased compared with the groups treated with R2636 and IR at times other than 6 h post infection (P¼0.036). This is consistent with our previous studies where we showed that combining oncolytic HSV-1 with IR resulted in significantly greater U87-xenograft regression starting at day 10 post initiation of therapy through day 60 (ref.
11). We also tested if combining IR with oncolytic HSV-1 resulted in increased tumor-xenograft regression in another glioma cell line, D54 (Supplementary Figure 1) . IR was given 24 h post intratumoral viral injection. The combination of HSV and IR resulted in significantly greater tumor regression than IR alone or virus alone (Po0.04).
HSV-1 late gene promoter activation exhibits a dose response to ionizing radiation We then determined if an IR dose response to enhance oncolytic HSV-1 gene expression existed. Glioma xenografts were injected with R2636 at day 0, time 0 h and then 0, 1, 2, 5, 10 or 20 Gy of IR was delivered 6 h post viral injection, the optimal temporal sequence from the above series of experiments (Figures 1 and 2 ). Viral luciferase expression was measured 4 days following injection ( Figure 3 ). Viral luciferase expression increased with increasing doses of IR from 0 to 5 Gy after which the detection of luciferase leveled off up to 20 Gy. The combined groups of 5, 10 and 20 Gy had significantly higher luciferase expression than non-irradiated tumors (P¼0.012). As increasing doses of IR result in greater cell kill, these data suggest that at a minimum 5 Gy should be delivered to take advantage of the effect of IR on viral replication.
DISCUSSION
In this series of studies, we have shown that the interaction of IR with the HSV-1 lytic cycle can be manipulated for a therapeutic gain. Viral replication occurs in a temporal sequential cascade of gene expression of immediate-early, early, and late gene expression. 8 Ionizing radiation's effects on cellular gene expression is also temporal, suggesting a favorable sequence of oncolytic virus and IR delivery. In our preclinical animal tumor model system, the replicative and oncolytic potential of attenuated HSV-1 is optimized by delivering IR at a specific period within sequential cascade of the viral replicative cycle (Figure 4a ). While delivering radiation at other times in the viral lytic cycle enhanced viral replication and increased tumor regression as compared with non-irradiated tumors, delivering IR 6-9 h into the course of viral infection resulted in the largest increase in viral transcription as measured by viral encoded luciferase expression. Enhanced viral gene expression correlated with increased production of infective viral particles and maximal glioma-xenograft regression (Figures 1 and 2 ). While the current studies measured immediate effects of IR on viral replication and tumor regression, our previous studies have shown long-term tumor-xenograft regression in glioma flank models and survival in glioma intracranial models when IR is combined with oncolytic HSV-1 (refs 11, 17) . To our knowledge this is the first report showing how optimally delivering IR with oncolytic virus results in increased viral gene expression, infectious viral particle production and tumor-xenograft regression. Differential glioma xenograft responses as a consequence of only altering the temporal sequence of IR and HSV-1 directly implicate an interaction of IR and HSV-1 in mediating enhanced glioma-xenograft regression. IR-enhanced oncolysis has been shown to occur through transcriptional and posttranslational changes of cellular and viral proteins (Figure 4a) . 23 In regards to HSV-1, viral ICP0 has been shown to interfere with IR-mediated DNA damage repair through its actions on DNA-activated protein kinase. 18 IR has been shown to increase transcription of cellular genes that trans-complement viral gene deletions (that is, ribonucleotide reductase and growth arrest and DNA damage 34) (refs 19-21) . Moreover, IR enhances transcription of viral late promoters by phosphorylating and activating p38 mitogen-activated protein kinase. 22 These multiple mechanisms of IR-mediated enhancement of HSV-1 viral replication are supported by our data. IR delivered at various time points in the HSV-1 replicative cycle increased viral replication, suggesting the pleiotropic role of IR in enhancing viral replication. However, IR-mediated enhancement of viral replication was greatest when IR was delivered 6-9 h following viral infection. The increased tumor-xenograft regression observed when IR is delivered at this time point post viral injection compared with other time points provides direct evidence for the interactive nature of IR and oncolytic HSV-1. Interestingly, the second best time to deliver IR was 24 h post viral injection. One explanation for this result may be the fact that it takes approximately 16-18 h for HSV-1 to replicate, therefore, giving IR 24 h after infection may represent 6 h into the course of the replicative cycle of progeny virus (that is, second life cycle) from the initial viral injection (Figure 4b) .
The other major radiotherapeutic parameter is the dose of IR to deliver following oncolytic HSV-1 injection. Our data indicate a radiation dose response from 0 to 5 Gy after which a plateau is reached at 20 Gy. This has several important clinical implications. Radiotherapy has traditionally been delivered in 2 Gy fractions to a total dose of 60 Gy for high-grade gliomas. 1 Technological advancements in the delivery of radiotherapy have allowed for altered fractionation schemes to be delivered, such as hypofractionated (5 Gy fractions) and higher radiosurgical doses (20 Gy). 26, 27 Moreover, critical structure tolerances (such as the brainstem or optic chiasm) to IR guide the choice of radiation dose that can be safely delivered. Our data suggest that a single radiation dose of 5 Gy may be sufficient to enhance viral replication and serve as the basis for future clinical trials with oncolytic HSV-1 and radiotherapy to enhance viral gene expression and infectious viral production. A recent study has shown that the dose rate of IR is also an important consideration when combining IR with oncolytic viruses. 28 Phase I clinical trials have already begun to explore the feasibility of combining oncolytic viruses with radiotherapy. [29] [30] [31] A clinical trial has also been undertaken to demonstrate the safety and feasibility of combining IR (single 5 Gy fraction) and oncolytic HSV-1 (JM Markert, personal communication). The data from the current study in part provided the basis for this trial in which radiotherapy is rationally integrated into the viral replicative cycle. These data suggest a new therapeutic role for IR in cancer therapy, that in addition to its inherent tumoricidal activity, IR can enhance viral gene expression and replication that results in increased tumor regression. In such a treatment paradigm, the spatial and temporal regulation of IR delivery is used to increase the therapeutic ratio of attenuated oncolytic viruses.
MATERIALS AND METHODS
Cells and viruses
Vero and U-87MG (glioma) cell lines were obtained from American Type Culture Collection. R3616 was derived from HSV-1(F) and lacks both copies of g 1 34.5 as described previously. 10 R2636 is also a HSV-1 mutant deleted for both copies of g 1 34.5, but encodes the luciferase gene under the control of the HSV-1 gC promoter as described previously. 22 Glioma xenograft bioluminescence imaging U-87MG xenografts were grown in the right hindlimb of athymic nude mice by subcutaneous injection of 1Â10 7 cells in 100 ml of PBS. For timing experiments, tumor xenografts were injected simultaneously with 2Â10 7 pfu R2636 in 10 ml of buffer at time defined as day 0, time 0 h from the same aliquot of stock of virus. IR (20 Gy) was given at time points before or after viral injection as indicated in the Results, as described previously, using a superficial X-ray generator. 11 Luciferase expression was imaged serially in mice from days 1 through 7 post injection using an IVIS 200 Imaging System (Caliper Life Sciences, Hopkinton, MA, USA) and Living Image software (Caliper Life Sciences). Before imaging, mice were intraperitoneally. injected with D-luciferin (15 mg kg À1 ) and anesthetized with xylazine (5 mg kg À1 ) and ketamine (75 mg kg À1 ). Glioma xenografts were imaged 15 min after luciferin injection. For radiation dose response experiments, tumor xenografts were injected with 2Â10 7 pfu of R2636 on day 0 at time 0 h from the same aliquot of stock virus. Six hours after viral injection 0, 1, 2, 5, 10 or 20 Gy was delivered. Tumor xenografts were imaged for luciferase expression 4 days post viral injection. All animal studies were done in accordance with the University of Chicago Animal Care and Use Committee standards.
Glioma xenograft viral titers
U-87MG xenografts were injected with 2Â10 7 pfu of R3616 on day 0, time 0 h from the same aliquot of virus. IR (20 Gy) was given at time points before or after viral injection as indicated in the Results. Three days post viral injection, tumor xenografts were harvested and infectious viral particles were quantified on Vero cells as described previously. 11 
Glioma-xenograft regression studies
Mice imaged for luciferase expression also had their tumor xenografts measured biweekly as described previously. 11 Fractional tumor volume is defined as the tumor volume at the specified day divided by the initial tumor volume (V/V 0 ).
Statistical analysis
One-tailed t-tests were performed using Microsoft Excel to compare experimental groups with untreated controls. We and others have previously shown that IR increased oncolytic HSV-1 replication. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The hypothesis tested in this series of experiments was that if varying the timing of IR in relation to the timing of viral injection would result in a further enhancement of viral replication.
